Calling the shots — postexposure prophylaxis against viruses by Hardie, D
Questions about encounters with viral dis-
ease and post-exposure prophylaxis (PEP)
are very common in general practice, and
are frequently referred to us for a special-
ist opinion.This article is intended to pro-
vide a quick guide to the action that can
be taken (if any) when a patient has been
exposed to a viral disease, whether in the
community or hospital setting.
It is worth bearing in mind that many of
the following diseases can cause asympto-
matic infection and exposed individuals
may unknowingly already be immune. So
it is often worth while to send a blood
sample to the laboratory to check for pre-
existing immunity before starting prophy-
laxis since results can usually be obtained
within a few hours.
Preventing viral infection relies on three
modalities: passive immunisation
(immune globulins), vaccination or anti-
viral therapy. PEP strategies are all sum-
marised in Table I.
A common concern that can be addressed
at the outset, relates to uncertainty
regarding the safety of immune globulin
preparations, particularly with regard to
the possibility of HIV infection.The man-
ufacturing processes used in immune
globulin preparation are geared to inacti-
vate viruses and other organisms, and the
preparations licensed in South Africa are
very safe. Similarly, modern viral vaccines
have a good safety profile although possi-
ble side-effects of the individual vaccines
should be conveyed to patients.
A final general point to consider is that
while post-exposure measures may abro-
gate clinical disease, in many cases sub-
clinical infection will occur.This means
that recipients of PEP may be infectious
after the usual incubation period, and can
themselves pose a risk of transmitting
infection to other susceptible contacts.
MEASLES
Measles is highly infectious. The virus is
shed in respiratory secretions and has an
attack rate of  more than 90% in suscepti-
ble household contacts. The disease has a
high morbidity especially in children less
than 1 year of age. In South Africa, out-
breaks occur from time to time among
unvaccinated individuals or vaccinated
individuals with waning immunity. Both
human normal immunoglobulin (HNIG)
and measles vaccine (given within 72
hours of exposure) can be used to prevent
or attenuate an attack in exposed individ-
uals. Immunoglobulin is preferred for
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MUMPS
Mumps virus circulates freely in
South Africa because there is no
national childhood vaccination pol-
icy. There is no evidence that post-
exposure administration of either
normal immunoglobulin or mumps
vaccine will protect an individual
from clinical disease. Fortunately,
serious complications are rare.
RUBELLA
Like mumps, rubella circulates
freely in South Africa. It is rarely
associated with significant compli-
cations other than in instances of
fetal infection. Infection in the first
trimester of pregnancy is associat-
ed with serious congenital abnor-
malities in approximately 80% of
cases. If infection occurs beyond
18 weeks of gestation, rubella no
longer poses a risk to the fetus.
There is no form of PEP that is of
proven efficacy for preventing fetal
infection and fetal abnormalities.
For women for whom termination
of pregnancy is not an option, the
administration of a high dose of
human normal immune globulin
(750 mg) intramuscularly as soon
as possible post exposure is
advised. This does not prevent
infection, but it may reduce the
viraemia, attenuate the clinical dis-
ease, and reduce the risk to the
fetus.
INFLUENZA
Influenza is highly infectious and
has a significant morbidity and
mortality in the very young and the
elderly. Annual vaccination
remains the most effective way of
preventing influenza. However,
prophylaxis with certain anti-
influenza drugs is also effective in
protecting against disease when
vaccination has been neglected. As
the incubation period for influenza
is short (48 hours), prophylaxis
needs to be given very promptly.
There are two contexts where PEP
for influenza has been used:
• to control an outbreak in an
institution  
• to prevent secondary cases with-
in a family.
Prophylaxis may be requested in
other contexts, for example by
leading sports people taking part in
a competitive event during a peri-
od of recognised influenza activity
(such as occurred during the
Olympic games in Sydney in
2000).
In South Africa two antiviral
agents are available for treatment
and prophylaxis of influenza.
Amantadine has been available for
many years, but it has activity
against influenza A only, and has
significant side-effects. The newer
neuraminidase inhibitors,
zanamivir (administered by inhala-
tion) and oseltamivir (orally) have
activity against both influenza A
and B and have few side-effects.
Only zanamivir is currently
licensed in South Africa.The use
of these drugs for influenza pro-
phylaxis is described in Table I.
VARICELLA
Chicken pox is highly infectious,
with an attack rate of 90% in sus-
ceptible household contacts.
Transmission occurs through respi-
ratory secretions as well as contact
with skin lesions, including the
skin lesions of shingles. Note that
patients with shingles may be a
source of  chicken pox infection,
but the converse is not true; con-
tact with chicken pox does not lead
to  shingles!
Three agents can be used as PEP
to prevent clinical chicken pox  or
reduce disease severity:
• Zoster immune globulin (ZIG)
is a high-titre preparation of
human antibody against varicel-
la zoster virus (VZV), prepared
from the serum of people who
have recently had shingles. It
contains a defined quantity of
anti-VZV antibodies, expressed
in international units (IU). ZIG
is in relatively short supply and
should be reserved for patients
who are at the highest risk of
serious complications (see
below).
• Varicella live attenuated vaccine
was licensed for use in South
Africa in 2002.
• Aciclovir and related drugs
(valaciclovir, famciclovir)  have
specific activity against herpes
simplex and varicella zoster
virus, but the effective oral dose
for varicella zoster is four times
higher.
The recommended form of PEP
following VZV exposure depends
on the context:
• Healthy non-immune con -
tacts . Either vaccine (if given
< 72 hours post exposure) or
prophylactic aciclovir (from day
7 to 21 post-exposure) is suit-
able.
• Pregnant women. Varicella
may cause more severe disease
in pregnant women, especially in
the third trimester. If infection
occurs in the first 20 weeks of
pregnancy, there is a small risk
(2%) of congenital varicella syn-
drome. Thus a seronegative
woman who has been exposed
to chicken pox at any stage of
pregnancy should receive ZIG.
If ZIG is not available, aciclovir
is regarded as a safe second
option in pregnancy.
• Neonates . The risk of  severe
chicken pox in neonates and
pre-term infants is greatest
(30% mortality) when the infant
lacks protective maternal anti-
varicella antibodies. The usual
scenario is when the mother
develops chicken pox during the
final days of her pregnancy. If
the mother’s rash emerges 7 or
more days before delivery, the
baby will be protected by mater-
MAIN TOPIC
C M E J u n e  2 0 0 3   Vo l . 2 1   N o . 6   327
nal antibody at birth and is not
at risk. If, however, the disease
erupts within 7 days of delivery
and up to 28 days post delivery,
the baby is unprotected and
should be given prophylaxis in
the form of ZIG. Eruption of
shingles in the mother during
pregnancy or in the perinatal
period is not regarded as a seri-
ous risk to the baby as it will be
protected by maternal antibody.
Note that babies of varicella-
immune mothers are protected
by maternal antibody in the
neonatal period, but this immu-
nity soon wanes, rendering the
infant susceptible by 2 - 3
months of age. Effectively, post-
exposure ZIG is probably advis-
able for any infant up to the age
of 6 months.
• Immunocompromised
patients . In this group, children
with haematological malignan-
cies are particularly at risk.
Although varicella causes a
higher rate of complications in
those infected with HIV, it does
not usually result in fulminant
disease. Nevertheless, post-
exposure prophylaxis is still
advised.The varicella vaccine
has been shown to be safe and
effective for most categories of
immunocompromised patients.
However, the protective efficacy
of post-exposure vaccine may be
lower than in healthy recipients,
and ZIG is advised in this con-
text.
HEPATITIS A
Hepatitis A virus (HAV) has a sig-
nificant morbidity in adults and
may (rarely) be fatal at any age.
The prevalence is high in South
Africa, but varies in different com-
munities. In poorer communities,
most people are infected in child-
hood, but in more affluent com-
munities, up to 50% of adults will
have no immunity. The hepatitis
A virus is shed in the stool and is
acquired by ingestion.
There are two approaches to pro-
tecting non-immune individuals
following hepatitis A exposure,
namely passive immunisation by
administration of antibody or
active immunisation with a vac-
cine:
• Human normal immunoglobu-
lin (HNIG) contains a defined
amount of anti-HAV antibody
that provides short-lived protec-
tion. With the advent of an
effective vaccine, the use of
HNIG for hepatitis A prophy-
laxis is declining.
• Hepatitis A vaccine is a cell cul-
ture-derived, formalin-inactivat-
ed vaccine. Either HNIG or the
vaccine, or both, can be used for
hepatitis A prophylaxis. The rec-
ommendations are given in
Table I.
HEPATITIS B
In the medical setting , hepatitis B
virus (HBV) is mainly spread by
percutaneous exposure to blood
and body fluids of infected individ-
uals, with the risk of transmission
as high as 60% when the source is
e antigen-positive (Fig. 1). How-
ever, in the community, transmis-
sion occurs more commonly
through sex or close personal con-
tact, and the disease prevalence
peaks in toddlers and again in
young adults. About 5% of adults
and a greater percentage of child-
ren will go on to be chronically
infected. Childhood vaccination
against hepatitis B, initiated in
South Africa in 1995, should
reduce the disease prevalence with-
in two decades. Post exposure,
infection can be prevented in non-
immune individuals with the use of
immune globulin or vaccine.
• Hepatitis B immune globulin
(HBIG) is prepared from serum
of immune individuals. It con-
tains a defined amount of anti-
body to the surface protein of
hepatitis B (surface antibody).
• Hepatitis B vaccine consists of
purified hepatitis B surface pro-
tein (surface antigen).The
serum-derived vaccine is pre-
pared from the serum of hepati-
tis B carriers and the recombi-
nant vaccine is synthesised in
yeast through recombinant
DNA technology.They are
equally safe and effective.
Vaccine alone, or HBIG and




exposure. Sexual partners, chil-
dren and individuals in the same
household as a (newly identi-
fied) HBV-infected individual
are at risk of infection and
should be vaccinated, if they are
not already immune.
• Non-immune contact with
definite exposure. In instances
such as occupational exposure
to a HBV-positive source, or
perinatal exposure when the
mother is an HBV carrier, both
HBIG and initiation of vaccina-
tion are indicated, within 72
hours (see Table I).
• Vaccinated contacts with def -
inite exposure. See Table I for
guidelines.
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• Rape. The prevalence of hepati-
tis B in South Africa and the
highly infectious nature of the
virus are reasons for routine
hepatitis B vaccination following
rape. In the unusual circum-
stance that the perpetrator is
known to be a hepatitis B carri-
er, HBIG is indicated as well.
HEPAT I T IS C
H e p atitis C virus (HCV) is another
parenterally transmitted cause of
h e p at i t i s , with the risk after percu-
taneous exposure estimated to be
around 2%. Infection is also trans-
mitted ve rtically (mother to child)
and through sexual contact, but the
risk is low. Up to 80% of infected
p atients fail to clear the virus and
are at risk of chronic liver disease.
There is no effective PEP for
h e p atitis C. Health care wo r k e rs
who are exposed to infected blood
should be monitored, as early treat-
ment of hepatitis C infection is
more effective than if it is delaye d .
The exposed person should be test-
ed for HCV RNA at 6 and 12
weeks after exposure and for HCV
antibody at 12 and 24 we e k s.
RA BIES
A detailed description of rabies
PEP is not feasible in this art i c l e .
R e a d e rs are referred to the
D e p a rtment of Health website for
c o m p r e h e n s i ve inform ation and
contact details and state sources of
vaccine and rabies immunoglobu l i n
( available on the internet at
h t t p : / / w w w. n b i - k z n . o r g . z a / i n t e r -
est/ contrabi.htm ) .W h at follow s
is an outline of the DOH guide-
l i n e s.
In South A f rica dog bites are the
cause of most of the 20 - 30 annual
human cases of rabies and geo-
graphically most of these cases
occur in KwaZu l u - N at a l .The ri s k
of contracting rabies following a
bite by a rabid animal va ri e s
according to the site and seve rity of
the bite(s), but overall the figure is
around 50%. Rabies carries a
100% mortality in humans.T h e
decision to embark on prophy l a x i s
depends on an assessment of the
likelihood that the attacking animal
was rabid. Should there be a possi-
bility that the animal was rabid, t h e
extent of the prophylactic measures
depends on the seve rity of the
exposure (bite ve rsus superficial
s c r atch or licking of broken skin).
An eva l u ation of the risk of rabies
in the animal can be based on 5
q u e s t i o n s :
• Is rabies prevalent in the area?
• Was the animal abnormal in any
way ?
• Was the attack unprovo k e d ?
• Is the animal known to have
been exposed to rabies?
• Was the animal immunised
against rabies?
If the answer to any of the first four
questions is yes (or don’t know) or
the answer to question 5 is no (or
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d o n ’t know ) , p r o p hylaxis should be
i n i t i at e d . Under no circumstances
should prophylaxis be delaye d
awaiting confirm ation of the diag-
nosis in the animal.
In many instances it is difficult to
rule out the possibility of exposure
and if a query remains, a ‘ b e t t e r
safe than sorry ’ approach should
p r e va i l . E ven late reporting of pos-
sible rabies exposure must be
assessed and treat e d . There is no
cut-off time for starting rabies PEP.
Rabies prophylaxis invo l ves the use
of a combination of vaccine and
i m m u n o g l o bu l i n :
• Human anti-rabies immunoglob-
ulin is prepared from the seru m
of rabies vaccine recipients.
Since the purpose of the
immune globulin is to neutralise
the viru s , as much globulin as
possible should be infiltrat e d
around the wo u n d .
• The rabies vaccine used in
South A f rica is an inactivat e d ,
cell culture-deri ved va c c i n e
which is completely safe. B i t e
victims who have been previous-
ly immunised should receive 2
booster doses of va c c i n e
( i m m u n o g l o bulin is not indicat-
e d ) .
Note that the sites of injection of
rabies vaccine and immune globu-
lin are critical (see Table I.) 
HUMAN IMMUNO-
DEFICIENCY VIRUS (HI V )
The general practitioner is often
faced with a situation where there
is a definite risk of  HIV infection
and PEP is clearly indicat e d ; f o r
example after occupational expo-
sure or  rape. H owe ve r , cases may
a rise where the appropri ate inter-
vention is less clear cut, for exam-
p l e , an injudicious sexual encounter
(‘one night stand’), a good
S a m a ritan helping at an accident
s i t e , or highly anxious individuals
presenting with a wide range of
possible exposure situations from
the feasible to the highly improba-
b l e . In these contexts common
sense and compassion must be
e xe r c i s e d , and PEP may or may not
be necessary.
Occupational exposure
In the health care setting, HIV is
spread by percutaneous or mucocu-
taneous (typically a splash in the
e ye) exposure to infected blood or
body fluids. The average risk of
transmission is 0.3% and  0.1%
r e s p e c t i ve l y. Used as PEP, a n t i -
r e t r oviral drugs selectively block
steps in the virus replication cy c l e
and prevent establishment of an
i n f e c t i o n . Animal studies and fol-
l ow-up studies of occupat i o n a l
exposures have confirmed that
these drugs are indeed effective .
I n t e rn ational recommendations are
for a two- or three-drug PEP regi-
m e n , where three drugs are gi ve n
for higher risk exposures (see Ta b l e
I ) , although there are no direct dat a
s u p p o rting the use of the 2nd and
3rd dru g s. The two - d rug regi m e n
consists of two nucleoside reve rs e
t r a n s c riptase inhibitors. If the
usual combination of zidov u d i n e
(AZT) and lamivudine (3TC) is
poorly tolerat e d , AZT can be
replaced by stavudine (D4T).
Al t e rn at i ve l y, a combination of
D4T and didanosine (dd1) can be
u s e d . For the three-drug regi m e n , a
protease inhibitor is added, u s u a l l y
i n d i n av i r , although Kaletra
( l o p i n av i r / ri t o n avir) may be a better
choice due to the lower potential
for toxicity (Gary Maart e n s , p e r-
sonal communicat i o n ) . A l t h o u g h
nevirapine would seem to be ideal
for PEP, it is precluded from the
r e c o m m e n d ations because of a few
cases of severe (fatal) hepat i t i s
o c c u rring during 28-day prophy l a c-
tic therapy.
If there is reason to suspect that the
source virus is dru g - r e s i s t a n t , t h e
p r o p hylactic regimen would need
to be devised accordingly, u s u a l l y
with a three-drug regi m e n .
Since the potential benefits of HIV
PEP usually outweigh the ri s k s ,
PEP is recommended for exposed
pregnant wo m e n , although the safe-
ty of none of the antiretrov i r a l
d rugs in pregnancy is cert a i n . M o s t
safety data exist for the use of A Z T,
and prophylaxis with AZT as a sin-
gle agent is advised for women who
h ave been exposed in the first 14
weeks of pregnancy.
It is imperat i ve that the drugs be
gi ven as soon as possible after
exposure (preferably within 1
h o u r ) , but they may still be effec-
t i ve if gi ven up to 72 hours post
e x p o s u r e . The longer the delay, t h e
higher is the risk of fa i l u r e . A n i m a l
studies support the efficacy of a 4-
week regi m e n . There are no dat a
on whether a shorter course of
therapy would be as effective .
Most antiretroviral drugs have side-
effects and may be poorly tolerat e d .
PEP recipients should be fore-
wa rn e d ; symptoms may be man-
ageable with additional medicat i o n s
such as an antiemetic, and analge-
sia for headache.Toxicity monitor-
ing depends on the toxicity profile
of the drugs used as prophy l a x i s.
For the standard AZT/3TC combi-
n at i o n , a full blood count and live r
function tests should be done at the
b e ginning of therapy and repeat e d
2 - 4 weeks lat e r.
P r o p hylaxis recipients should be
counselled and advised to practise
safe sex until the three-month fol-
l ow-up test.
Rape or injudicious sexual
encounter 
The risk of HIV transmission
through sexual contact is approx i-
m ately 0.1 - 1% per sexual
encounter (somewhat higher for
r e c e p t i ve anal sex), but is presumed
to be increased in the case of rape.
Usually the HIV status of the
a s s a i l a n t / p a rtner is unknow n . R a p e
victims should therefore be offered
a n t i r e t r oviral prophy l a x i s , w h i c h
should be initiated along with pro-
p hylactic measures against other
S T D s , within 72 hours of the
a s s a u l t .The same regimens used
for occupational exposures are
a p p r o p ri at e .
Mother-to-child transmission 
P r o p hylaxis in the context of 
mother-to-child transmission is not
s t rictly PEP and is beyond the
scope of this art i c l e . H owe ve r , if a
n e o n ate has been exposed to HIV
d u ring delive ry and the mother’s
s t atus is only discovered afterwa r d s ,
the baby should be gi ven prophy-
laxis with AZT (2 mg/kg 
6 hourly) for 6 we e k s. I d e a l l y, ther-
apy should be started within 72
hours of birth.
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IN A NUTSHELL
C e rtain viral infections can be pre v e n t-
ed in susceptible contacts with the
timeous use of vaccines, immunoglob-
ulin or antiviral drugs.  
Active immunisation post exposure is
usually the most effective means of
p reventing infection with hepatitis A,
B, measles, rabies and varicella.  
If PEP is delayed, or the patient has
had a high-risk exposure, a combina-
tion of immunoglobulin and vaccine is
a d v i s e d .
Live attenuated vaccines are con-
t r a i n d i cated in immunocompro m i s e d
patients, very young babies and pre g-
nant women, and these individuals
should receive immuno-globulin only,
for example following exposure to
varicella or measles.
Specific antiviral drugs can be used to
p revent HI V, influenza or varicella.
Wh e re no reliable prophylaxis is avail-
able, ca reful follow-up and early inter-
vention are essential, for example
after rubella exposure in pre g n a n c y
and hepatitis C exposure in health
ca re workers.
